WO2000078325A1 - Synergistic compositions containing lycopene and silymarin for treatment of liver disease - Google Patents

Synergistic compositions containing lycopene and silymarin for treatment of liver disease Download PDF

Info

Publication number
WO2000078325A1
WO2000078325A1 PCT/IL2000/000352 IL0000352W WO0078325A1 WO 2000078325 A1 WO2000078325 A1 WO 2000078325A1 IL 0000352 W IL0000352 W IL 0000352W WO 0078325 A1 WO0078325 A1 WO 0078325A1
Authority
WO
WIPO (PCT)
Prior art keywords
lycopene
accordance
composition
silymarin
extracted
Prior art date
Application number
PCT/IL2000/000352
Other languages
French (fr)
Inventor
Zohar Nir
Jeorg Gruenwald
Claus Peter Siegers
Original Assignee
Lycored Natural Products Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IL13055699A priority Critical patent/IL130556D0/en
Priority to IL130556 priority
Application filed by Lycored Natural Products Industries Ltd. filed Critical Lycored Natural Products Industries Ltd.
Publication of WO2000078325A1 publication Critical patent/WO2000078325A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A23B - A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Abstract

The present invention provides a novel synergistic composition comprising lycopene and sylimarin and its use in treating liver diseases. The composition of the invention is further effective as a free oxygen radical scavenger, thus the composition of the invention is effective in treating liver diseases induced by free oxygen radical formation.

Description

SYNERGISTIC COMPOS ITIONS CONTAIN ING LYCOP ENE AND SI LYMARIN FOR TREATMENT OF LIVER DISEASE
Field of the Invention
The present invention concerns a composition containing lycopene and sUymarin. The present invention more particularly concerns the synergistic mixture of both lycopene and sUymarin and its use in the treatment of acute, subacute and chronic liver diseases,
Background of the Invention
Toxic nutritive liver diseases are the most frequent metabolic diseases of the modem world, in particular the alcohol-induced liver diseases like alcohol hepatitis, alcohol-induced fatter liver hepatitis and alcohol-induced liver cirrhosis. Free oxygen radical formation is found to be involved in ethanol-induced hepatotoxicity in experimental models and in man (Younes and Strubelt, 1987).
Lycopene is a β-carotinoid with radical-scavenging properties. Among other radical-scavengers like thiols or flavonoids, lycopene is specialized to scavenge singlet-oxygen (Gerster, 1997). This action results in a protection of hepatocytes against carbon tetrachloride induced injury and lipid peroxidation (Kirn, 1995).
SUymarin is an extract of mild thistle fruits containing three main flavonoids, silibinin, silidianin and silicristin (Wagner et al., 1968), a class of flavonolignanes.
Three main mechanisms of hepatoprotection are discussed:
1. Stimulation of RNA-polymerase 1 in the cell nucleus and thereby stimulation of liver cell regeneration (Sonnenbichler and Zetl, 1984)
2. Stabilization of lipid cell membranes
3. Antiperoxidative properties by scavenging free radicals (Feher and co workers, 1987)
Clinical experiences with sUymarin-containing drugs have proven efficacy in the treatment of toxic liver diseases (Ferenci et al., 1989; Fintelmann and Albert, 1980; Floersheim et al., 1980). Even, adjuvant treatment of chronic viral hepatitis and liver cirrhosis were reported (Kiescwetter et al., 1977; Ferenci et al., 1989).
Objectives It is an objective of the present invention to provide a novel synergetic pharmaceutical composition.
It is a further objective of the present invention to provide a novel synergetic dietary composition.
Yet an additional objective of the present invention is to provide a composition effective in treating liver disorders.
It is a further objective of the present invention to provide a mixture to scavenge free radicals of different origins in order to counteract the inflammation, toxic cell injury and lipid peroxidation involved in the alcohol-induced liver diseases such as alcohol hepatitis, alcohol-induced fatter liver hepatitis, and alcohol-induced liver cirrhosis.
Summary of the Invention The present invention provides a synergetic mixture comprising of lycopene and sUymarin. Furthermore, the present invention provides a method for inhibiting or preventing free oxygen radical formation in a subject, wherein said method comprises adrriinistering to a subject a free oxygen radical scavenging effective dose of the synergistic mixture of the present invention. Furthermore, the present invention provides a use of a novel synergistic mixture comprising lycopene and sylimarin in the preparation of a medicament for treating liver diseases. Additionally, the present invention provides a use of a novel synergistic mixture comprising lycopene and sylimarin in the preparation of a dietary composition. Further provided by the present invention is a pharmaceutical composition comprising lycopene and sylimarin. Description of the Drawings
Fig. 1 is a graph of GPT U I perfusate levels over time and is a comparison of ethanol; ethanol + dimethyl sulfoxide; and ethanol + silymarine.
Fig. 2 is a graph of GPT U/I perfusate levels over time and is a comparison of ethanol; ethanol + tetrahydrofuran + butylated hydroxytoluene; ethanol + lycopene; and ethanol + Lyc-O-mato®.
Fig. 3 is a graph of GPT U/I perfusate levels over time and is a comparison of ethanol; ethanol + dimethyl sulfoxide + tetrahydrofuran + butylated hydroxytoluene; ethanol + lycopene + silymarine; and ethanol + Lyc-O-Mato® + silymarine.
Fig. 4 is a graph of LDH U/I perfusate levels over time and is a comparison of ethanol; ethanol + dimethyl sulfoxide; and ethanol + silymarine.
Fig. 5 is a graph of LDH U/I perfusate levels over time and is a comparison of ethanol; ethanol + tetrahydrofuran + butylated hydroxytoluene; ethanol + lycopene; and ethanol + Lyc-O-mato®.
Fig. 6 is a graph of LDH U/I perfusate levels over time and is a comparison of ethanol; ethanol + dimethyl sulfoxide + tetrahydrofuran + butylated hydroxytoluene; ethanol + lycopene + silymarine; and ethanol + Lyc-O-Mato® + silymarine.
Fig. 7 is block diagram of GSH levels in the liver and is a comparison of ethanol; ethanol + dimethyl sulfoxide; and ethanol + silymarine.
Fig. 8 is block diagram of GSH levels in the liver and is a comparison of ethanol; ethanol + tetrahydrofuran + butylated hydroxytoluene; ethanol + lycopene; and ethanol + Lyc-O-mato®. Fig. 9 is block diagram of GSH levels in the liver and is a comparison of ethanol; ethanol + dimethyl sulfoxide + tetrahydrofuran + butylated hydroxytoluene; ethanol + lycopene + silymarine; and ethanol + Lyc-O-Mato® + silymarine.
Fig. 10 is block diagram of MDA levels in the liver and is a comparison of ethanol; ethanol + dimethyl sulfoxide + tetrahydrofuran + butylated hydroxytoluene; ethanol + lycopene + silymarine; and ethanol + Lyc-O-Mato® + silymarine.
Fig. 11 is block diagram of MDA levels in the liver and is a comparison of ethanol; ethanol + tetrahydrofuran + butylated hydroxytoluene; ethanol + lycopene; and ethanol + Lyc-O-mato®..
Fig. 12 is block diagram of MDA levels in the liver and is a comparison of ethanol; ethanol
+ dimethyl sulfoxide; and ethanol + silymarine.
Detailed Description of the Invention
The following description is illustrative of embodiments of the invention. The following description is not to be construed as limiting, it being understood that the skilled person may carry out many obvious variations. The present invention is based on the unexpected discovery that there is a surprising synergism between lycopene and silymarin in counteracting the free oxygen radical formation found to be involved in alcohol-induced liver diseases.
The source of lycopene can be tomato oleoresin, algal, fermented, fungal, genetically modified organism (GMO), synthetic lycopene, and mixtures thereof.
Lycopene and Lyc-O-mato®. (6% tomato oleoresin) were obtained from the Lycored Natural Products Industries Ltd. Silymarin extract was delivered by the Paul Muggenburg Company, Germany. The combination of silymarin and Lyc-O-mato® (the latter a 6% tomato oleoresin) was found to be most effective in counteracting the effects of alcohol-induced liver diseases such as alcohol-induced fatter liver hepatitis, and alcohol-induced liver cirrhosis.
The relative parts by weight of silymarin to lycopene is from 50: 1 to 1 :250, preferably 30: 1 to 1:30.
Ethanol hepatotoxicity could be tested in an ex-vivo model because of high ADH-activities which are necessary for the ethanol metabolism and oxygen radical formation (Younes and Strubelt, 1987). As a measure of hepatotoxic response to ethanol (3%o) the release of enzymes (LDH, GLDH, GPT) into the perfusate are determined in a time dependent manner and also functional parameters are looked at like perfusion flow, bile flow, oxygen consumption, glucose, lactate and pyruvate release into the perfusate. Biochemical parameters at the end of the perfusion in the livers give information on mechanistic aspects like lipid peroxidation (MDA), ATP-depletion or glutathione depletion (GSH/GSSG). Alterations in the liver weight are indicative of general toxicity (hydropic swelling of injure cells).
The composition of the present invention can be used straight or contain dietary components, additives, excipients, binding agents, coatings, preservatives, and mixtures thereof.
The composition of the present invention can be contained in a variety of dosage forms such as tablets, caplets, vegecaps, and hard shell gelatin capsules.
Examples
General
HepG2, a human hepatocellular tumor cell line (ATCC-Nr. HB 8065) was cultured in
RPM1/1640 /Boehringer, Mannheim, Germany) medium supplemented with 5% fetal calf serum and l% L-glutamine. The neutral-red assay was performed as a measure of cell growth according to Borenfreund and Puerrier (1984). Enzyme releases into the medium were a measure of cytotoxicity; LDH, GPT, GPT and GLDH were determined by using commercially available test kits (Boehringer and Sigma, Germany).
Perfusion of isolated rat livers with ethanol was performed according to published procedures from our lab (Younes and Strubelt, 1987; Deters et al., 1998).
Arithmetic means and their standard errors are given, IC50 value were calculated by graphic interpolation. Until now, checks for statistical significance of differences between means were not performed because of the problems of multiple comparisons.
Males Wistar rats (conventional animals, 320-380 gr breeder Winkelrnann, Borchen) were used throughout. They had free access to a standard diet (AJtromin pellets) and tap water.
Unless otherwise stated, reagents used for liver perfusion and biochemical determinations were of analytical grade and obtained from either Sigma Aldrich (Deisenhofen, FRG) or Merck (Darmstadt, FRG).
Removal of the liver and its connection to a recirculating perfusion system was performed as previously described (Strubelt et al., 1986). After removal of the livers, rats died by exsanguination. The albumin- and serum-free perfusion medium consisted of 259 ml Krebs Henseleit buffer, pH 7.4 (118 mmoVl NaCl, 6 mmol/1 KC1, 1.1 mmol/1 MGSO4 24 mmol/1 CaC-5). Sodium taurocholate (36.7 g/1) was infused into the perfusate at a rate of 1.2 ml/h to stimulate bile secretion. The perfusion medium was continuously gassed with carbogen (95% O2, 5% CO2) yielding an oxygen partial pressure of about 600 rnmHg. Perfusion was performed under conditions of constant pressure (240 mmiπo) throughout the experiment and the perfusion flow rate was initially regulated at 60 ml/min using a tube clamp. The experiments were started after a 30-min equilibration period (time 0) by adding ethanol (130.2 mmol/1) to the perfusate before they were finished 120 rnin later. Oxygen consumption of the isolated perfused livers was calculated by measuring the differences in oxygen concentrations between the influent and affluent perfusate using a micro pH/blood gas analyzer 1306 (Instrumentation Laboratory). Perfusion flow was determined every 30 rnin by damming up the effluent perfusate in a special vial without imp-airing the perfusion flow and measuring the volume after 20 s. Bile was sampled every 30 rnin and the rate of bile secretion was calculated in g Uver/min. For biochemical determinations, samples of 2 ml were also taken from the perfusate every 30 rnin. Livers were weighed before connecting them to the perfusion system. At the end of the experiments they were frozen in liquid nitrogen until further analysis.
The activities of GPT, LDH and GLDH were assayed using commercial kits from Bochringer Mannheim (Mannheim, FRG). Perfusate enzyme concentrations were distributed normally as checked by the method of Sachs (1978). Malondialdehyde (MDA) was measured both in the perfusate and livers by coupling to thiobarbituric acid (Buege and Aust, 1978). Total glutathione was determined in liver and perfusate samples according to Brehe and Burch (1976). Oxidized glutathione (GSSG) was estimated by the same procedure after blocking GS11 with 2-vinylpyridine (Griffith, 1980). For ATP determination, hepatic tissue was frozen immediately in liquid nitrogen and extracts were prepared according to Williamson and Corkey (1969). Adenosine triphosphate (ATP) was assayed enzymatically using a reagent kit from Sigma (Munich, FRG).
Example 1
GPT enzyme released into the perfusate is markedly depressed by the combination of silymarin and lycopene:
GPT U/I Perfusate
(a) Control 45 (See Fig.1,2,3)
(b) 130.2 mmol/1 ethanol 310
(c) 10 mg/1 Silymarin + (b) 90 (See Fig.1)
(d) 300 mg/1 Lyc-O-mato® + (b) 300 (See Fig.2)
(e) 10 mg/1 Lycopene + (b) 300 (See Fig.2)
10 mg/1 Silymarin + 300 mg/1 Lyc-O-mato® 100 (See Fig.3) + (b) (g) 10 mg/1 Silymarin + 10 mg/1 Lycopene + (b) 80 (See Fig.3)
Example 2
LDH enzyme released into the perfusate is markedly depressed by the combination of silymarin and Lyc-O-mato®
LDH U/I Perfusate
(a) Control 500 (See Fig.4, 5, 6)
(b) 1130.2 mmol/1 ethanol + (b) 3100
(c) 10 mg/1 Silymarin + (b) 1085 (See Fig.4)
(d) 300 mg/1 Lyc-O-mato® + (b) 3000 (See Fig.5)
(e) 10 mg/1 Lycopene + (b) 3000 (See Fig.5)
10 mg/1 Silymarin + 300 mg/1 Lyc-O-mato® 750 (See Fig.6) + (b) (g) 10 mg/1 Silymarin + 10 mg/1 Lycopene + (b) 2600 (See Fig.6) Exa ple 3
MDA is markedly decreased by the combination of silymarin and lycopene or
Lyc-O-mato®:
MDA nmol/g liver
(a) Control 16.5 (See Fig. lo,:
(b) 130.2 mmol/1 ethanol 22.5
(c) 10 mg/1 Silymarin + (b) 17.5 (See Fig. 10)
(d) 300 mg/1 Lyc-O-mato® + (b) 14 (See Fig. 11)
(e) 10 mg/1 Lycopene + (b) 20 (See Fig. 11)
10 mg/1 Silymarin + 300 mg/1 13 (See Fig. 12) Lyc-O-mato® + (b) (g) 10 mg/1 Silymarin + 10 mg/1 Lycopene + (b) 14 (See Fig. 12)
Example 4
GSH depletion is markedly inhibited by the combination of silymarin and lycopene or
Lyc-O-mato®:
GSH μmol/g liver
(a) Control 3.5 (See Fig. 7, 8, 9)
(b) 130.2 mmol/1 ethanol 2.3
(c) 10 mg/1 Silymarin + (b) 3.6 (See Fig. 7)
(d) 300 mg 1 Lyc-O-mato® + (b) 4.2 (See Fig. 8)
(e) 10 mg/1 Lycopene + (b) 3.3 (See Fig. 8)
10 mg/1 Silymarin + 300 mg/1 Lyc-O-mato® 4.75 (See Fig. 9) + (b) (g) 10 mg/1 Silymarin + 10 mg/1 Lycopene + (b) 4.2 (See Fig. 9)
While embodiments of the invention have been described by way of illustration, it will be apparent that the invention may be carried out with many modifications, variations and adaptations, without departing from its spirit or exceeding the scope of the claims.

Claims

1. A synergistic pharmaceutical or dietary composition which comprises lycopene and silymarin.
2. A composition in accordance with Claim 1 wherein the lycopene is selected from the group consisting of lycopene from tomato oleoresin, algal, fermented, fungal, genetically modified organism (GMO), synthetic lycopene, and mixtures thereof.
3. A composition in accordance with Claim 1 wherein the lycopene is selected from the group consisting of lycopene and tomato oleoresin.
4. A composition in accordance with Claim 1 which comprises synthetic lycopene.
5. A composition in accordance with Claim 1 wherein the sπymarin is extracted from the Silybum marianum plant.
6. A composition in accordance with Claim 1 wherein the sUvmarin is extracted from the fruit of the Silybum marianum plant.
7. A composition in accordance with Claim 1 wherein the silymarin is extracted from the Silybum marianum plant and is standardized on a silybin content between 75% and 90%.
8. A composition in accordance with Claim 1 wherein the relative parts by weight of suymarin to lycopene is from 50:1 to 1 :50 preferably 30:1 to 1 :30.
9. A composition in accordance with any of Claims 1 to 8 wherein the composition contains compounds selected from the group consisting of dietary components, additives, excipients, binding agents, coatings, preservatives, and mixtures thereof.
10 A composition in accordance with any of Claims 1 to 9 wherein the composition is contained in dosage forms selected from the group consisting of tablets, caplets, vegecaps and hard shell gelatin capsules.
Use of a synergistic composition containing lycopene and silymarin for the preparation of pharmaceutical compositions for treatment of acute, subacute and chronic liver diseases.
A use in accordance with Claim 1 1 wherein the lycopene is selected from the group consisting of lycopene from tomato oleoresin, algal, fermented, fungal, genetically modified organism (GMO), synthetic lycopene, and mixtures thereof.
A use in accordance with Claim 11 wherein the diseases are selected from the group consisting of alcohol-hepatitis and alcohol-induced fatter liver hepatitis and alcohol induced liver cirrhosis.
A use in accordance with Claim 11 wherein the lycopene is tomato oleoresin.
A use in accordance with Claim 1 1 which comprises synthetic lycopene.
A use in accordance with Claim 1 1 wherein the silymarin is extracted from the Silybum marianum plant.
A use in accordance with Claim 11 wherein the silymarin is extracted from the fruit of the Silybum marianum plant.
A use in accordance with Claim 1 1 wherein the suymarin is extracted from the Silybum marianum plant and is standardized on a sirybin content between 75% and 90%.
A use in accordance with Claim 1 1 wherein the relative parts by weight of silymarin to lycopene is from 50:1 to 1:50 preferably 30:1 to 1 :30.
A use in accordance with any of Claims 11 to 19 wherein the composition contains compounds selected from the group consisting of dietary components, additives, excipients, binding agents, coatings, preservatives, and mixtures thereof.
A use in accordance with any of Claims 11 to 20 wherein the composition is contained in dosage forms selected from the group consisting of tablets, caplets, vegecaps and hard shell gelatin capsules.
A method for combating acute, subacute, and chronic liver diseases which comprises contacting the liver with a synergistic mixture of lycopene and silymarin.
A method in accordance with Claim 22 wherein the lycopene is selected from the group consisting of lycopene from tomato oleoresin, algal, fermented, fungal, genetically modified organism (GMO), synthetic lycopene, and mixtures thereof.
A method in accordance with Claim 22 wherein the lycopene is selected from the group consisting of lycopene and tomato oleoresin.
A method in accordance with Claim 22 which comprises synthetic lycopene.
A method in accordance with Claim 22 wherein the silymarin is extracted from the Silybum marianum plant.
A method in accordance with Claim 22 wherein the silymarin is extracted from the fruit of the Silybum marianum plant.
A method in accordance with Claim 22 wherein the silymarin is extracted from the Silybum marianum plant and is standardized on a silybin content between 75% and 90%.
A method in accordance with Claim 22 wherein the relative parts by weight of silymarin to lycopene is from 50: 1 to 1:50 preferably 30: 1 to 1:30. A method in accordance with any of Claims 22 to 29 wherein the composition contains compounds selected from the group consisting of dietary components, additives, excipients, binding agents, coatings, preservatives, and mixtures thereof.
A method in accordance with any of Claims 22 to 30 wherein the composition is contained in dosage forms selected from the group consisting of tablets, caplets, vegecaps and hard shell gelatin capsules.
Use of a composition claimed in claim 1 for preventing or inhibiting the free oxygen radical formation found to be involved in alcohol-induced liver diseases.
PCT/IL2000/000352 1999-06-20 2000-06-16 Synergistic compositions containing lycopene and silymarin for treatment of liver disease WO2000078325A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IL13055699A IL130556D0 (en) 1999-06-20 1999-06-20 Synergistic compositions for treatment of liver diseases
IL130556 1999-06-20

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU52443/00A AU5244300A (en) 1999-06-20 2000-06-16 Synergistic compositions containing lycopene and silymarin for treatment of liver disease
EP00937159A EP1194155A1 (en) 1999-06-20 2000-06-16 Synergistic compositions containing lycopene and silymarin for treatment of liver disease

Publications (1)

Publication Number Publication Date
WO2000078325A1 true WO2000078325A1 (en) 2000-12-28

Family

ID=11072942

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2000/000352 WO2000078325A1 (en) 1999-06-20 2000-06-16 Synergistic compositions containing lycopene and silymarin for treatment of liver disease

Country Status (4)

Country Link
EP (1) EP1194155A1 (en)
AU (1) AU5244300A (en)
IL (1) IL130556D0 (en)
WO (1) WO2000078325A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011076154A1 (en) 2009-12-22 2011-06-30 Irel, Spol. S R.O. Feed supplement based on milk thistle, method of its production and its use
WO2011076155A1 (en) 2009-12-22 2011-06-30 Irel, Spol. S R.O. Feed supplement based on milk thistle, method of its production and its use

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0659402A2 (en) * 1993-12-21 1995-06-28 INDENA S.p.A. Formulations containing carotenoids and procarotenoids combined with polyphenols in the prevention of the damages due to an abnormal production of free radicals
US5895652A (en) * 1996-07-29 1999-04-20 Longevity Institute International Method of metabolic adjuvanation and cellular repair
US5904924A (en) * 1997-11-04 1999-05-18 Oncologics, Inc. Green nutritional powder composition
WO1999048386A1 (en) * 1998-03-24 1999-09-30 Stueckler Franz Natural substance based agent
WO1999061038A1 (en) * 1998-05-29 1999-12-02 Adams Food Ltd. Composition having therapeutic and/or nutritionally active substituent

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0659402A2 (en) * 1993-12-21 1995-06-28 INDENA S.p.A. Formulations containing carotenoids and procarotenoids combined with polyphenols in the prevention of the damages due to an abnormal production of free radicals
US5895652A (en) * 1996-07-29 1999-04-20 Longevity Institute International Method of metabolic adjuvanation and cellular repair
US5904924A (en) * 1997-11-04 1999-05-18 Oncologics, Inc. Green nutritional powder composition
WO1999048386A1 (en) * 1998-03-24 1999-09-30 Stueckler Franz Natural substance based agent
WO1999061038A1 (en) * 1998-05-29 1999-12-02 Adams Food Ltd. Composition having therapeutic and/or nutritionally active substituent

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Bio-C3 complex is a unique synergistic combination of 10 antioxidants from herbal,vitamin and mineral sources", MATOL PRODUCTS, XP002153303, Retrieved from the Internet <URL:www.matol.com/products/antioxidants/product.htm> [retrieved on 20001114] *
FLORA K. ET AL: "Milk thistle (Sylibum marianum) for the Therapy of liver disease", AMERICAN JOURNAL OF GASTROENTEROLOGY, vol. 93, no. 2, 1998, pages 139 - 143, XP000965734 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011076154A1 (en) 2009-12-22 2011-06-30 Irel, Spol. S R.O. Feed supplement based on milk thistle, method of its production and its use
WO2011076155A1 (en) 2009-12-22 2011-06-30 Irel, Spol. S R.O. Feed supplement based on milk thistle, method of its production and its use

Also Published As

Publication number Publication date
AU5244300A (en) 2001-01-09
IL130556D0 (en) 2000-06-01
EP1194155A1 (en) 2002-04-10

Similar Documents

Publication Publication Date Title
Vogel et al. Protection by silibinin against Amanita phalloides intoxication in beagles
US7276257B2 (en) Schisandrin B preparation
Nuhu et al. Effects of Cassia occidentalis aqueous leaf extract on biochemical markers of tissue damage in rats
Khalil et al. The inhibitory effects of garlic and Panax ginseng extract standardized with ginsenoside Rg3 on the genotoxicity, biochemical, and histological changes induced by ethylenediaminetetraacetic acid in male rats
Uma et al. Moringa oleifera enhances liver antioxidant status via elevation of antioxidant enzymes activity and counteracts paracetamol-induced hepatotoxicity.
Saravanan et al. Impact of Hemidesmus indicus R. Br. extract on ethanol-mediated oxidative damage in rat kidney
Gamal-Eldeen et al. Evaluation of antioxidant, anti-inflammatory, and antinociceptive properties of aerial parts of Vicia sativa and its flavonoids
Airaodion et al. Hepatoprotective potency of ethanolic extract of Garcinia kola (Heckel) seed against acute ethanol-induced oxidative stress in Wistar rats
Gupta et al. Anti–hepatotoxic potential of Hedyotis corymbosa against D–galactosamine–induced hepatopathy in experimental rodents
Hsieh et al. Protective effects of Cholestin on ethanol induced oxidative stress in rats
Omotayo et al. Hepatoprotective effect of Mangifera-indica stem bark extracts on paracetamol-induced oxidative stress in albino rats
A Tohamy et al. Cinnamic acid attenuates cisplatin-induced hepatotoxicity and nephrotoxicity
Tahari et al. Protective effect of Haloxylon salicornicum on hepatic and renal functions of Wistar rats exposed to aluminium
WO2000078325A1 (en) Synergistic compositions containing lycopene and silymarin for treatment of liver disease
Ramarajan et al. Nephroprotective effects of Colpomenia sinuosa (Derbes & Solier) against carbon tetrachloride induced kidney injury in Wistar rats
Prommetta et al. Aqueous extract of the calyces of Hibiscus sabdariffa Linn: effects on hepatic cytochrome P450 and subacute toxicity in rats
Njinga et al. Toxicity assessment of sub-acute and sub-chronic oral administration and diuretic potential of aqueous extract of Hibiscus sabdariffa calyces
KR20060106065A (en) Hepato-protective effects of angelica keiskei root extract, 4-hydroxyderricin and xanthoangelol
Adewale et al. PROTECTIVE EFFECT OF ETHANOLIC EXTRACT OF CRASSOCEPHALUM RUBENSLEAVES ON CARBON TETRACHLORIDE-INDUCED LIVER DAMAGE IN RATS
Ahmed et al. Silymarin and hydroethanolic extracts of Silybum marianum leaves and fruits attenuate diethylnitrosamine/phenobarbital-induced nephrotoxicity via their antioxidant and anti-inflammatory actions
Alinezhad et al. Assessing the protective effect of Primula heterochroma Stapf extracts against sodium fluoride-induced hemolysis in rat erythrocytes
Oyewole et al. Hepatorenal Protective Activities of Plantain Root (Musa paradisiaca) on Arsenic-induced Oxidative Damage in Rat
MOSBAH et al. Protective effect of Nigella sativa oil and its neutral lipid fraction on ethanol-induced hepatotoxicity in rat model
Mahmoud et al. Anti-diabetic activity of the chloroform extract of Senecio mikanioides Otto in streptozotocin-induced diabetic rats.
Komolafe et al. Protective effects of extract and fraction of root-bark of Garcinia kola (Heckel) on the renal biochemical parameters of gentamicin-induced nephrotoxic rats

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2000937159

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000937159

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000937159

Country of ref document: EP

NENP Non-entry into the national phase in:

Ref country code: JP